<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="211">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669028</url>
  </required_header>
  <id_info>
    <org_study_id>NM101</org_study_id>
    <nct_id>NCT04669028</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of NE3107 in Probable Alzheimer's Disease</brief_title>
  <official_title>A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioVie Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioVie Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      U.S. multicenter, parallel group study designed to evaluate the safety and efficacy of oral&#xD;
      20 mg twice daily (BID) NE3107 vs placebo in 316 adult subjects with mild to moderate&#xD;
      probable AD. Two coprimary outcome measures (the Alzheimer's Disease Assessment Scale&#xD;
      Cognitive Subscale 12 [ADAS Cog12] and the Alzheimer's Disease Cooperative Study Clinical&#xD;
      Global Impression of Change [ADCS CGIC] will be evaluated as the change from Baseline to Week&#xD;
      30. Secondary endpoints include measures of neuropsychological deficits, functional&#xD;
      performance, and glycemic control. A subset of patients may volunteer for exploratory&#xD;
      magnetic resonance imaging (volumetric changes) and positron emission tomography (cortical&#xD;
      glucose metabolic rate) scans at baseline and week 30.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Alzheimer's Disease Assessment Scale Cognitive Subscale 12 [ADAS Cog12]</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>series of questions to measure cognitive function, score 0-70, 0 = no impairment, 70 = most severe impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS CGIC]</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>series of questions to measure cognitive functional and behavioral characteristics scored 1-7 with 1 being greatest improvement and 7 being most severe worsening of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study Activities of Daily Living Scale</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>23 item scale with total score of 0-78, with a lower score indicating worse disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Exam (MMSE)</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>30 questions with a total score of 0-30, with a lower score indicating worse disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Index 12</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>12 questions with total score 0-12, with higher score indicating worse disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease clinical COMposite Score (ADCOMS)</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>composite score of questions from different cognitive test. total score ranges from 0-1.97, with higher scores indicating worse disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic assessment of insulin resistance 2 (HOMA2-IR)</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>blood tests for insulin and glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial glucose excursions</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>3-day average of postprandial glucose measure by continuous glucose monitoring</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Resource Utilization in Dementia (short version, Lite)</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
    <description>compiles data on the use of social services, frequency and duration of hospitalizations, unscheduled contacts with health care professionals, use of concomitant medications by both the caregiver and the patient, amount of time the caregiver spends caring for the patient and missing work, and patients' use of study medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>volumetric magnetic resonance imaging (vMRI)</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>cortical metabolic rate using fluorodeoxyglucose positron emission</measure>
    <time_frame>baseline and week 30 (end of study)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>NE3107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hard gelatin capsule containing 20 mg micronized NE3107 drug substance blended with common excipients for oral formulations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hard gelatin capsule containing only common excipients for oral formulations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NE3107</intervention_name>
    <description>NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.</description>
    <arm_group_label>NE3107</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules that do not contain NE3107</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Male or female subject aged 60 to 85 y at Screening (V1). 2. Has mild to moderate&#xD;
             probable AD as defined by all of the following criteria:&#xD;
&#xD;
               1. Meets the National Institute on Aging and Alzheimer's Association (NIA-AA, 2011)&#xD;
                  criteria of all cause dementia and probable AD.&#xD;
&#xD;
               2. Has a Clinical Dementia Rating (CDR) (Section 8.1.6) Standard Global Score of 1&#xD;
                  to 2, inclusive (mild to moderate).&#xD;
&#xD;
               3. Has a MMSE score of ≥14 and ≤24 at both Screening and Baseline visits. The&#xD;
                  difference in scores between Screening and Baseline must be &lt; 3 points (i.e., the&#xD;
                  difference must not exceed 3 points). (Section 8.1.5)&#xD;
&#xD;
               4. Has an historical MRI or CT scan of the brain on file no earlier than AD&#xD;
                  diagnosis that fails to exhibit features of another potential pathobiology that&#xD;
                  could better account for the cognitive disorder.&#xD;
&#xD;
                  3. Historical evidence of impairment on a mental status exam or documented prior&#xD;
                  diagnosis of or treatment for dementia from a health care professional.&#xD;
&#xD;
                  4. Has a modified Hachinski Ischemic Scale (Section 8.1.8) score of ≤4 at&#xD;
                  Screening (V1).&#xD;
&#xD;
                  5. If taking an anticholinesterase inhibitor (AChEI) (e.g., donepezil,&#xD;
                  galantamine, rivastigmine) and/or memantine at Screening (V1):&#xD;
&#xD;
               1. Must have been taking the medication(s) for ≥3 mo, and&#xD;
&#xD;
               2. Current dose regimen and form must have remained stable for ≥6 wk and must remain&#xD;
                  stable throughout participation in the study.&#xD;
&#xD;
                  NOTE: Subjects not being treated with an AChEI and/or memantine at Screening (V1)&#xD;
                  may also be enrolled if initiation of an AChEI and/or memantine is not planned&#xD;
                  for the time period during which the subject will be participating in this study.&#xD;
&#xD;
                  NOTE: Dosage changes during the study due to clinical deterioration should be&#xD;
                  discussed with the Medical Monitor prior to being implemented.&#xD;
&#xD;
                  6. If taking medications for glycemic control at the time of Screening (V1), must&#xD;
                  be stable on the current dose regimen and form for ≥3 mo prior to randomization&#xD;
                  and must remain stable throughout participation in the study.&#xD;
&#xD;
                  7. Females taking hormone replacement therapy (HRT) must have maintained a stable&#xD;
                  regimen for at least two years prior to randomization and agree to continue the&#xD;
                  regimen until completing the final safety assessment in Week 30 at the end of the&#xD;
                  study.&#xD;
&#xD;
                  8. Must meet one of the following criteria:&#xD;
&#xD;
               1. Females: Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or&#xD;
                  tubal ligation) for at least 6 mo prior to Screening (V1) or postmenopausal&#xD;
                  (postmenopausal females must have no menstrual bleeding for at least 1 y; if&#xD;
                  needed, the Investigator may confirm menopausal status through an FSH assessment&#xD;
                  at Screening [V1]). 6.8.1&#xD;
&#xD;
               2. Males: Vasectomized. If not vasectomized, must use an appropriate contraception&#xD;
                  method as noted in Section 6.8.1.&#xD;
&#xD;
                  9. Must provide voluntary written informed consent prior to Screening (V1). If&#xD;
                  the subject is unable to provide informed consent due to cognitive status, the&#xD;
                  subject must provide assent and a legally authorized representative provides full&#xD;
                  written informed consent on behalf of the subject.&#xD;
&#xD;
                  10. Willing to allow collection of blood for ApoE genotyping. 11. Able to comply&#xD;
                  with the study procedures, in the opinion of the Investigator.&#xD;
&#xD;
                  12. Has a primary caregiver/study partner willing to accept responsibility for&#xD;
                  supervising the treatment (e.g., administering study drug), accompanying the&#xD;
                  subject to clinic visits and assessing the condition of the subject throughout&#xD;
                  the study in accordance with all protocol requirements. The primary&#xD;
                  caregiver/study partner must be willing to sign the caregiver ICF.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  1. Has prior brain imaging inconsistent with probable AD 2. A history of a stroke that&#xD;
             resulted in a cognitive or motor deficit or, MRI or CT evidence of a moderate or large&#xD;
             cerebral infarct.&#xD;
&#xD;
               1. Should there be any evidence of neurologic symptoms between the date of the scan&#xD;
                  confirming diagnosis and Screening (V1), rescanning is necessary.&#xD;
&#xD;
                  3. Has clinically relevant abnormal laboratory tests including serum vitamin B12&#xD;
                  deficiency, thyroid function abnormality, severe anemia, or electrolyte&#xD;
                  abnormality.&#xD;
&#xD;
                  4. Diagnosis of type 1 diabetes or type 2 diabetes requiring insulin treatment or&#xD;
                  the need to use continuous glucose monitoring. Subjects who become insulin&#xD;
                  dependent during the study may not continue to participate in the study.&#xD;
&#xD;
                  5. History of epilepsy or seizure disorder requiring ongoing treatment, or any&#xD;
                  seizure or loss of consciousness within 12 mo prior to Screening (V1).&#xD;
&#xD;
                  6. Subjects are ineligible, if in the opinion of the investigator, they have&#xD;
                  deficits in speech, comprehension, auditory functioning, or vision which would&#xD;
                  adversely impact their ability to perform the study's cognitive test procedures,&#xD;
                  complete rating scales, or engage in interviews.&#xD;
&#xD;
                  7. Has any of the following laboratory findings at Screening (V1):&#xD;
&#xD;
               1. Alanine aminotransferase &gt;3 × upper limit of normal (ULN), aspartate&#xD;
                  aminotransferase &gt;3 × ULN, or history of clinically significant liver disease in&#xD;
                  the Investigator's medical judgment.&#xD;
&#xD;
               2. Hemoglobin ≤10 g/dL.&#xD;
&#xD;
               3. International normalized ratio &gt;1.5 if not on anticoagulant medication; if the&#xD;
                  subject is on anticoagulant medication, the anticoagulant medication should be&#xD;
                  optimized and on a stable dose for ≥4 wk prior to Screening (V1).&#xD;
&#xD;
               4. Creatinine clearance (Cockcroft Gault formula) of &lt;45 mL/min.&#xD;
&#xD;
               5. Known to be seropositive for human immunodeficiency virus (1 and 2), hepatitis B,&#xD;
                  or hepatitis C. Subjects with hepatitis C who had spontaneous resolution or&#xD;
                  received successful curative treatment (e.g., HARVONI® [ledipasvir/sofosbuvir])&#xD;
                  with a documentation of undetectable viral load for at least 3 mo may be allowed.&#xD;
                  Serological testing will not be performed as part of this study.&#xD;
&#xD;
                  8. Female subjects with child-bearing potential (premenopausal, menstrual&#xD;
                  bleeding within the last 12 months) or who are pregnant or breastfeeding.&#xD;
&#xD;
                  9. History of any medical illness such as cancer requiring systemic therapy in&#xD;
                  the last 5 y, except for localized basal cell carcinoma of the skin, in situ&#xD;
                  cervical cancer successfully treated with surgical excision, and stable (for ≥90&#xD;
                  d prior to Screening [V1]) prostate cancer.&#xD;
&#xD;
                  10. History of breast cancer. 11. History of severe heart failure (Grade 2 or&#xD;
                  higher on the New York Heart Association scale), major stroke, uncontrolled&#xD;
                  seizure disorder, or other medical illness that, in the Investigator's opinion,&#xD;
                  will increase the subject's risk of participation in the study or confound study&#xD;
                  assessments.&#xD;
&#xD;
                  12. Any surgery requiring general anesthesia that is planned to occur during the&#xD;
                  study. Local anesthesia during outpatient surgery is permitted if, in the opinion&#xD;
                  of the Investigator, the operation will not interfere with study procedures and&#xD;
                  subject safety.&#xD;
&#xD;
                  13. History or current evidence of major psychiatric illness such as&#xD;
                  schizophrenia, bipolar disorder, or major depressive disorder that may interfere&#xD;
                  with the subject's ability to perform the study and all assessments.&#xD;
&#xD;
               1. Geriatric Depression Scale Short Form (GDS SF) score &gt;8 at Screening (V1). NOTE:&#xD;
                  Mild depression or depressive mood arising in the context of AD are not criteria&#xD;
                  for exclusion. The use of anti epileptic medication for non-seizure-related&#xD;
                  treatment or the use of antidepressants is allowed if the dose has remained&#xD;
                  stable for ≥60 d prior Screening (V1).&#xD;
&#xD;
                  14. Violent or aggressive behavior that may interfere with study participation&#xD;
                  15. History of active suicidal thoughts (Type 4 or 5 on the C SSRS) in the 6 mo&#xD;
                  prior to Screening (V1) or at Baseline (V2), history of a suicide attempt in the&#xD;
                  previous 2 y or &gt;1 lifetime suicide attempt, or are at serious suicide risk, in&#xD;
                  the Investigator's clinical judgment.&#xD;
&#xD;
                  16. History of alcohol or drug abuse or dependence within 24 mo of Screening (V1)&#xD;
                  as defined by the Diagnostic and Statistical Manual of Mental Disorders 5.&#xD;
&#xD;
               1. Positive urine screen for drugs of abuse that include methadone, cocaine, and&#xD;
                  amphetamines; positive urine screen for opiates, barbiturates, or benzodiazepines&#xD;
                  without a prescription.&#xD;
&#xD;
                  17. Has participated in another Investigational New Drug research study involving&#xD;
                  small molecule drugs within 60 d or biological drugs within 90 d prior to the&#xD;
                  first dose of study drug in this study (Baseline [V2]) or within 5 half-lives of&#xD;
                  the other investigational medicinal product, whichever is longer.&#xD;
&#xD;
                  18. History of Covid-19 (SARS-CoV-2) infection within 6-weeks prior to screening.&#xD;
                  Subjects with unresolved symptoms of Covid-19 infection or ongoing cognitive or&#xD;
                  other deficits attributable to post-Covid-19, that may affect participant safety&#xD;
                  or interfere with efficacy assessments, based on the Investigator's clinical&#xD;
                  judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clarence Ahlem, MS</last_name>
    <phone>858-255-4568</phone>
    <email>cahlem@bioviepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Reading, PhD</last_name>
    <phone>858-255-4542</phone>
    <email>creading@bioviepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Perseverance Research Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>480-471-6132</phone>
      <email>bmccravey@prcresearcheducation.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Endpoints</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>480-566-9090</phone>
      <email>clbrown@clinicalendpoints.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tucson Neuroscience Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>520-230-1373</phone>
      <email>mailto:amilkovica@tucsonneuroscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WR-PRI</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>818-705-7450</phone>
      <email>ybarrera@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WR-PRI</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead study coordinator</last_name>
      <phone>949-752-7910</phone>
      <email>kkim@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cordova Clinical Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>916-701-2003</phone>
      <email>dryusufzai@cordovaclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integrity Clinical Research, LLC</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>305-552-7660</phone>
      <email>vmasyrubi@icrsites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reliable Clinical Reseach</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>786-536-4177</phone>
      <email>jmateu@reliablecr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>305-805-0921</phone>
      <email>luisp@galizresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charter Research</name>
      <address>
        <city>Lady Lake</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>352-775-1000</phone>
      <email>jessica.sletten@charterresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Accel Research-Lakeland Clinical Research Unit</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mae Clinical Research Coordinator</last_name>
      <phone>863-940-4726</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites-Maitland Clinical Research Unit</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>407-644-1165</phone>
      <email>ewierzbicki@accelclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>386-785-2400</phone>
      <email>lcamacho@accelclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Life Medical Research Group</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>South Florida Research Phase I-IV</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>305-418-0849</phone>
      <email>lrevoredo@southfloridatrials.coom</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMG Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>clinical research coordinator</last_name>
      <phone>305-646-1322</phone>
      <email>crc1@lmgresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocean Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>786-536-7999</phone>
      <email>karinc@oceanclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Future Care Solution</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>EZY Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>786-483-8162</phone>
      <email>phernandez@ezytrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coral Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>786-362-6114</phone>
      <email>yaima@coralmiami.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nuovida Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>New York Neurology Associates</name>
      <address>
        <city>New York</city>
        <state>Florida</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>917-633-5549</phone>
      <email>shumaila@nyneurologists.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adaptive Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venus Thornhill, CMA</last_name>
      <phone>877-734-2588</phone>
      <email>vthornhill@seagaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinCloud</name>
      <address>
        <city>Viera</city>
        <state>Florida</state>
        <zip>32940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>786-536-4177</phone>
      <email>jmateu@reliablecr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Conquest Research, LLC</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa O'Neill, MS</last_name>
      <phone>407-916-0600</phone>
      <email>melissa.oneill@conquestresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMITA Health Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>847-981-2045</phone>
      <email>Jeanine.Pilat@amitahealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>702-893-8968</phone>
      <email>akill@crcnnv.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Institute</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Study Coordinator</last_name>
      <phone>732-807-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>732-930-1321</phone>
      <email>Jessica@bbhnj.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>718-317-5522</phone>
      <phone_ext>1303</phone_ext>
      <email>kgennaro@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>718-317-5919</phone>
      <email>ncorona@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMC Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>704-364-4000</phone>
      <phone_ext>241</phone_ext>
      <email>tboheler@amcneurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>614-293-9023</phone>
      <email>brooke.eiginger@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KCA Neurology</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>615-550-1800</phone>
      <email>jcowan@kcadocs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KCA Neurology</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lead study coordinator</last_name>
      <phone>931-434-0959</phone>
      <email>jcowan@kcadocs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memory Clinic</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>802-447-1409</phone>
      <email>olivia@memorydoc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reading CL, Ahlem CN, Murphy MF. NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021 Aug;11(4):289-298. doi: 10.2217/nmt-2021-0022. Epub 2021 Jul 12.</citation>
    <PMID>34251287</PMID>
  </reference>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>September 26, 2022</last_update_submitted>
  <last_update_submitted_qc>September 26, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

